10.27.17
Bristol-Myers Squibb
3Q Revenues: $5.3 billion (+7)
3Q Earnings: $856 million (-30%)
YTD Revenues: $15.3 billion (+8%)
YTD Earnings: $3.3 billion (-6%)
Comments: Eliquis sales were up 39% in the quarter to $1.2 billion. Opdivo sales were $1.3 billion, up 38%. Yervoy sales were up 13% to $323 million. Orencia sales were up 10% to $632 million. Sprycel sales were up 8% to $509 million. Hep C Franchise sales were down 81% to $73 million. Baraclude sales were down 14% to $264 million. Sustiva Franchise sales were down 33% to $183 million and Reyataz Franchise sales were down 27% to $174 million. R&D expenses increased 36% to $1.5 billion in the quarter primarily due to the IFM Therapeutics (IFM) acquisition charge of $310 million.
3Q Revenues: $5.3 billion (+7)
3Q Earnings: $856 million (-30%)
YTD Revenues: $15.3 billion (+8%)
YTD Earnings: $3.3 billion (-6%)
Comments: Eliquis sales were up 39% in the quarter to $1.2 billion. Opdivo sales were $1.3 billion, up 38%. Yervoy sales were up 13% to $323 million. Orencia sales were up 10% to $632 million. Sprycel sales were up 8% to $509 million. Hep C Franchise sales were down 81% to $73 million. Baraclude sales were down 14% to $264 million. Sustiva Franchise sales were down 33% to $183 million and Reyataz Franchise sales were down 27% to $174 million. R&D expenses increased 36% to $1.5 billion in the quarter primarily due to the IFM Therapeutics (IFM) acquisition charge of $310 million.